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Abstract
Dysplasia epiphysealis hemimelica (DEH) and metachondromatosis (MC) are considered
in the differential diagnosis of solitary and hereditary osteochondromas. Both are rare
disorders with DEH demonstrating cartilaginous overgrowth of an epiphysis and MC
exhibiting synchronous enchondromas and osteochondromas. Ten cases of DEH and
two of MC were compared with osteochondromas at the histological and molecular
level. Histologically, clumping of chondrocytes within a fibrillary chondroid matrix is
characteristic of DEH, while osteochondromas and MC display the characteristic growth
plate architecture. Using cDNA microarray analysis we demonstrate that DEH and MC
cluster separately from osteochondromas and growth plates. The EXT genes, involved in
the hereditary multiple osteochondromas syndrome, and downregulated in osteochondroma,
were normally expressed in DEH and MC as shown by quantitative reverse transcriptase-
polymerase chain reaction (qPCR). EXT is involved in heparan sulphate biosynthesis,
important for Indian Hedgehog/ParaThyroid Hormone Like Hormone (IHH/PTHLH)
growth plate signalling pathways. IHH/PTHLH signalling molecules were expressed in DEH
and MC as shown by both qPCR and immunohistochemistry, suggesting that this pathway is
active. This is in contrast to osteochondroma, in which PTHLH signalling is downregulated.
Thus, lesions of DEH and MC are separate entities from osteochondroma as confirmed by
their different cDNA and protein expression profiles. Downstream targets of EXT, which
are downregulated in osteochondroma, are expressed in DEH and MC, suggesting that EXT
signalling is not disturbed.
Copyright  2006 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Dysplasia epiphysealis hemimelica (DEH, Trevor’s
disease, tarso-epiphyseal aclasis) and metachondro-
matosis (MC) are extremely rare disorders to be con-
sidered in the clinicoradiological and histological dif-
ferential diagnosis of solitary or hereditary osteochon-
dromas.
Osteochondromas are the most common benign
bone tumours [1]. They are cartilage-capped bony
outgrowths on the external surface of bone and con-
tain a marrow cavity that is continuous with that of
the underlying bone [1]. They develop in the first
decade of life, increase in size into the second decade,
and cease to grow when the growth plates close at
or after puberty. About one in six osteochondromas
arises within the context of Multiple Osteochondro-
mas (MO, HME, EXT, diaphyseal aclasis) [2], an
autosomal dominant orthopaedic disorder of multiple
osteochondromas, causing a variety of orthopaedic
deformities [3] (reviewed by Hameetman et al [4]).
The most important complication is malignant trans-
formation, estimated to occur in <1% of solitary cases
and 1–3% of cases of multiple osteochondromas [3].
DEH is a developmental disorder with cartilagi-
nous overgrowth of a portion of one or more epi-
physes or their equivalents, such as tarsal or carpal
bones. The reported incidence is 1 : 1 000 000 [5].
It predominantly affects the lower extremity on one
side of the body. It is usually restricted to either the
medial (most frequent) or lateral side of the limb
(hemimelic). Three different forms are recognized:
localized (monostotic), classic (more than one area in a
single extremity affected hemimelically), and general-
ized/severe (involving an entire single extremity) [6].
The classic form is most common. Similar to osteo-
chondroma, DEH is usually diagnosed before the age
of 15 years, more often in boys than in girls, and
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growth of these lesions end at puberty as the growth
plates close [5,7]. In contrast to MO, malignant trans-
formation has not been reported so far [5] and there
does not appear to be any genetic transmission [7–9].
Premature closure of the growth plate may lead to
limb deformity and limb length discrepancy. More-
over, premature secondary osteoarthritis may occur.
Histologically the lesion is alleged to be identical to
osteochondroma [9,10]. Distinction from osteochon-
droma is made based on the characteristic radiological
findings. Radiologically, DEH is characterized by a,
usually irregular, bony outgrowth of an epiphysis of
a tubular bone, a tarsal or carpal bone. Similar to
osteochondroma, the cortex and bone marrow of the
involved bone is continuous into (the basis of) this
outgrowth (Figure 1). The localization in an epiphysis
of a tubular bone, or in a tarsal or carpal bone is,
however, in contrast with a common osteochondroma.
MC is a rare disorder exhibiting synchronously both
multiple osteochondromas and enchondromas in chil-
dren. It has an autosomal dominant mode of inheri-
tance [11–13], but the disorder has not been mapped
in the human genome so far. MC-related osteochon-
dromas characteristically occur in the hands and feet,
predominantly the digits and toes, and point towards
the adjacent growth plate, while in MO the osteo-
chondromas are mainly located in the long or other
tubular bones and point away from the epiphysis [11].
The enchondromas, in contrast to enchondromas in
patients with enchondromatosis (Ollier disease, Maf-
fucci syndrome), mainly affect the iliac crests and the
metaphyses of long bones [11]. Avascular necrosis is
a frequent complication [14,15] and is hypothesized
to be caused by interference with the integrity of the
lateral epiphyseal vessels by the lesions [15]. Differ-
entiation from MO is of great clinical significance
Figure 1. Dysplasia epiphysealis hemimelica. (A, B) Radiographs of DEH lesions of the right ankle of patient 1. The fibular lesion
arises from the epiphysis and lies in close relation to the epiphyseal plate. The other lesions arise from the posterior and lateral
aspect of the talus and the posterior aspect of the calcaneus (arrows); (C) DEH lesion of the right distal femur of patient 5 (arrow);
(D) computed tomographic scan of the lesion shown in C, demonstrating all the radiological features of DEH; (E) micrograph of
the lesion shown in A. In most DEH cases the chondrocytes lie in small clusters; (F) magnification of E, clearly demonstrating the
fibrillary matrix around the chondrocyte clusters
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because in patients with MC the lesions do not result
in shortening or deformity of affected bones as in
MO, and may spontaneously decrease in size or
resolve completely, both clinically and radiologically
[11,13].
The molecular defect in both DEH and MC is
unknown and no molecular genetic studies have been
reported. In contrast, two genes, EXT1 and EXT2,
located respectively on chromosomal bands 8q24 and
11p11–p12, have been identified for MO [16–18].
EXT displays its function in the biosynthesis of hep-
aran sulphate (HS) proteoglycans, which are pre-
sumed to be important for diffusion of Indian Hedge-
hog (IHH), an important signalling molecule in the
IHH/ParaThyroid Hormone Like Hormone (PTHLH)
pathway that is responsible for chondrocyte prolifera-
tion and differentiation within the human growth plate.
We have previously demonstrated that EXT-related
signal transduction pathways are downregulated in
hereditary and solitary osteochondromas [19]. In the
present study, in addition to a histological and radi-
ological evaluation, expression profiles of DEH and
MC were compared with those of MO and the nor-
mal growth plate using cDNA microarray analysis as
well as quantitative polymerase chain reaction (PCR)




Thirteen cases from 12 patients diagnosed with DEH
or MC were retrieved from the files of the Netherlands
Committee on Bone Tumours, containing >13 800
bone tumours or tumour-like lesions collected over
the past 50 years. An additional case originated from
the files of the Department of Pathology, University
of Erlangen-Nurnberg, Germany. Radiological exam-
ination of all cases, including conventional X-rays
for all patients and additional computed tomography
or magnetic resonance imaging scans for some of
them, were reviewed by an expert bone tumour radi-
ologist (HMK). Histological slides were reviewed by
two specialist bone tumour pathologists (PCWH and
JVMGB). The diagnosis was confirmed in 12 cases
from 11 of the patients: two of MC and 10 of DEH.
Two cases of supposed DEH were excluded since the
diagnosis was changed to osteochondroma after radio-
logical and histological review. Table 1 and Figures 1
and 2 show the patient data. Fresh frozen tissue was
available in two cases for RNA isolation. All patient
material was coded such that code breaking and cor-
relation with clinical data were only possible for the
physicians treating the patients. Research was con-
ducted following the ethical guidelines of the national
organization of scientific societies (FEDERA; “Code
for Proper Secondary Use of Human Tissue in The
Netherlands”).
Histological evaluation
Histological criteria evaluated in DEH and MC cases
are as follows: binucleated cells (absent, few, mod-
erate, many), nuclear polymorphism (absent, moder-
ate [open nuclei], severe), nucleoli (absent, present),
distribution of cells (regular, irregular), clumping of
chondrocytes (Figure 1) (absent, present), cellularity
(low, intermediate, high), mitoses (absent, present),
mucomyxoid matrix changes (absent, present), growth
plate architecture (absent, partly present, complete),
demarcation towards soft tissue (sharp, unsharp),
fibrillary matrix (absent, present). A control group
of osteochondromas was gender and age matched,
including both actively growing, cellular lesions (in
very young patients) and more mature and quiescent
lesions, to avoid differences being due to different
maturity of the lesions. DEH and osteochondromas
were compared using the SPSS10.0 software pack-
age (SPSS Inc, Chicago, Illinois, USA) (Fisher’s exact
test).




diagnosis (years) Diagnosis Location of resection Other lesions
Family
history
1 M 4 DEH Distal fibula R Talus R, calcaneus R Unknown
2 M 5 DEH Proximal tibia R None Unknown
3 M 7 DEH Distal femur R Talus R Negative
4 F 41 DEH Distal fibula L 1st metatarsal L Unknown
5 M 12 DEH Distal femur R None Negative
6 F 3 DEH Distal tibia R None Unknown
7 M 5 DEH Talus R None Unknown
8 F 11 DEH Talus R Yes; see below Unknown
13 DEH Navicular/cuboid/cuneiform bone R
9∗ M 7 DEH Distal femur None Negative
10 F 5 MC Metacarpals 2 and 5 L, 2nd and 4th
digit R, metacarpal 1 R
Osteochondromas multiple digits,
enchondroma 3rd digit L
Negative†
11∗ M 6 MC 3rd and 4th digit R, 2nd metacarpal L Enchondroma proximal femur R Unknown
∗ Fresh frozen tissue available for RNA expression analysis.
† Mutation analysis for EXT1 and EXT2 was negative.
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Figure 2. Metachondromatosis. (A) Radiograph of the pelvis of patient 11 with an enchondroma in the right proximal femur
(arrow) adjacent to the apophysis of the greater trochanter; (B) radiograph of both hands of patient 10. Multiple osteochondromas
pointing towards the epiphyses. Enchondroma in the proximal phalanx of the left third digit (arrow); (C, E) micrographs of
osteochondroma-like lesions in metachondromatosis of patients 10 and 11, respectively; (D) magnification of C. These lesions are
histologically indistinguishable from conventional osteochondroma recapitulating the normal growth plate architecture
Immunohistochemistry
Antibodies and controls
Formalin-fixed paraffin-embedded tissue was available
for all 12 cases. Immunohistochemistry was performed
as described previously [20]. Table 2 shows details
of antibodies and controls. Commercially available
antibodies against IHH and PTCH were not shown
to work reliably in our hands and could therefore not
be used to study IHH signalling. The 10E4 antibody
reacts with an epitope that occurs in native HS chains
[21]. The antibodies were tested for their susceptibility
to formalin fixation using tissues fixed for 1–40 days
to avoid false negative results. None of the antibodies
showed diminished reactivity. For most antibodies,
internal controls were available in the histological
slides (Table 2) to exclude negativity of tumour cells
caused by prolonged decalcification.
Scoring and evaluation
Slides were scored as described previously [19] by two
observers independently (LH and JVMGB). Briefly,
staining intensity (0 = no staining; 1 = weak stain-
ing; 2 = moderate staining; 3 = strong staining) and
the percentage of positive cells (0 = 0%; 1 = 1–24%;
2 = 25–49%; 3 = 50–74%; 4 = 75–100% positive
tumour cells) were evaluated and the scores were
added. As described previously, a score >3 was con-
sidered positive. Statistical analysis was performed
with SPSS10.0 software. Immunohistochemical results
for DEH were compared with those obtained previ-
ously for osteochondromas using Fisher’s exact test.
These data were partly published previously (PTHLH
and BCL2 [22], p21 [19]). The median age of patients
with osteochondromas was higher than that of patients
with DEH and MC lesions (20.6 vs 6.5 years).
cDNA microarray analysis
mRNA was isolated as described [23] from frozen
material from one DEH (patient No 9) and one MC
case (No 11). cDNA microarray hybridization was
performed as described previously [24]. Results were
compared with those of six osteochondromas and four
postnatal normal growth plates that were hybridized
J Pathol 2006; 209: 411–419

































































































































































































































































































































































































































































































































simultaneously [25]. The array data were clustered by
unsupervized hierarchical clustering as described [26].
Quantitative PCR (qPCR)
Quantitative reverse transcriptase PCR experiments
were performed on the same two DEH and MC cases
as the microarray experiments. Total RNA (1 µg) was
reverse transcribed to complementary DNA (cDNA)
by using AMV Reverse Transcriptase (Roche Applied
Science, Penzburg, Germany). qPCR was performed
for EXT1, EXT2, IHH, PTCH, SMO, GLI2, PTHLH,
and three normalization genes (HNRPH1, CAPNS1,
and SRPR) (primers and qPCR conditions are avail-
able on request). We selected the normalization genes
from the expression profiling experiments of six osteo-
chondromas, 14 secondary peripheral chondrosarco-
mas, and four postnatal growth plates, with the least
variation between all the samples [25]. Normalization
was performed using the geNorm program [27]. qPCR
reactions were performed with the qPCR Corekit for
SybrGreen (Eurogentec, Seraing, Belgium) according
to manufacturer’s protocol and run on an iCycler (Bio-
Rad, Hercules, CA, USA). For each gene, a standard
curve, consisting of a mixture of eight samples, was
included to calculate the relative starting quantity of
each gene, used in normalization and statistical anal-
ysis. Results were compared with those of six osteo-




Osteochondromas tended to have partial or complete
growth plate architecture, while in DEH chondro-
cytes were predominantly clumped in small clusters
(Figure 1E). Moreover, fibrillary matrix was not seen
in osteochondromas, while it was present in all DEH
cases (Figure 1F). Histological features favouring the
diagnosis of DEH over osteochondroma were absence
or limited number of binucleated cells (p = 0.000),
presence of nucleoli (p = 0.040), clumping of chon-
drocytes (p = 0.002), absence or only partial pres-
ence of a growth plate architecture (p = 0.002), and
the presence of a fibrillary chondroid matrix (p =
0.000). Nuclear polymorphism (p = 0.221), the dis-
tribution of the cells (p = 0.078), cellularity (p =
0.192), mucomyxoid matrix degeneration (p = 0.293),
and demarcation towards the soft tissue (p = 0.095)
did not differ between the two lesions. Mitoses were
absent in both lesions.
Meaningful statistical analysis on the two MC cases
was not possible. They both showed absence of bin-
ucleated cells, some nuclear polymorphism, presence
of nucleoli, high cellularity, some mucomyxoid matrix
changes, absence of mitoses, complete growth plate
architecture, and a sharp demarcation towards the soft
J Pathol 2006; 209: 411–419
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tissue, while a fibrillary chondroid matrix was absent
(Figures 2C–E).
Radiological evaluation
Review of all radiological studies of the two cases
of MC and 10 cases of DEH demonstrated classical
radiographic criteria, eg bony outgrowths arising from
the epiphyses of tubular bones and/or tarsal bones
with continuity of both cortex and bone marrow
from the underlying bone into the lesions in cases of
DEH (Figure 1), and a synchronous combination of
enchondromas and osteochondromas pointing towards
the growth plate in cases of MC (Figure 2).
Immunohistochemistry
Table 3 summarizes the results. The protein expression
of PTHLH, PTHR1, and BCL2 in DEH cases indicates
that PTHLH signalling is active in DEH, while being
downregulated in osteochondromas (Table 3). PTHLH
and its downstream effector BCL2 expression were
significantly different (p = 0.011 and 0.001, respec-
tively) between DEH and osteochondroma.
In MC, PTHLH is also expressed, while this does
not lead to BCL2 expression. However, only one case
of MC could be evaluated for BCL2. Figure 3 shows
examples.
The expression of HS proteoglycans (syndecan-2
and HS-bearing variable exon 3 of CD44) and native
HS side chains in DEH and MC was not significantly
different from the expression in osteochondromas,
with the proteoglycans being expressed in the majority
of cases, while the native HS side chains were mostly
absent. The expression of the different proteins did not
correlate with gender or patient age.
cDNA microarray analysis
Unsupervized hierarchical clustering showed that DEH
(case 9) and MC (case 11) clustered separately from
solitary and MO and growth plates (Figure 4). Both
lesions still expressed cartilage specific markers such
as COL2A1, COL9A1, SOX9, and FGFR3 in a similar
fashion as the growth plates (data available upon
request).
qPCR
EXT1 mRNA was expressed in DEH (case 9) and
MC (case 11), but was decreased in osteochondro-
mas. Expression levels of EXT2 were higher in the
DEH and MC cases than in the three hereditary osteo-
chondromas, but similar to expression levels found in
three solitary osteochondromas. The expression levels
of IHH signalling genes in DEH and MC were sim-
ilar to those in osteochondromas, with the exception
of PTHLH, which was expressed more highly in both
DEH and MC. There were no differences in expres-
sion levels for all genes between DEH, MC and growth
plates. Table 4 summarizes the expression levels.
Discussion
We present a histological and molecular evaluation of
DEH and MC, two extremely rare disorders to be
considered in the differential diagnosis of Multiple
Osteochondromas. The distinction is made based on
a clinicoradiological evaluation since, histologically,
these lesions are often said to be identical. Osteo-
chondromas recapitulate normal endochondral bone
formation as the stratified zones of chondrocytes that
are normally found in the growth plate can most often
still be recognized histologically in osteochondroma,
be it somewhat disorganized [1]. Although we could
only evaluate two cases, the osteochondromas in MC
seemed histologically indistinguishable from sporadic
or hereditary osteochondromas, also recapitulating this
growth plate architecture. In contrast, this was much
less evident in DEH, in which clumping of chondro-
cytes, as previously described [8], surrounded by a
fibrillary matrix was a prominent feature (Figure 1).
In addition to the different histological features,
we demonstrate that DEH is also different from
osteochondroma at the molecular level. Unfortunately,
owing to its rarity, fresh frozen tissue to isolate high
quality RNA was available for only one DEH case.
DNA and RNA isolation from paraffin-embedded tis-
sue is not possible owing to usually extensive decal-
cification. However, although only one sample could
be evaluated, cDNA microarray analysis showed that
Table 3. Immunohistochemical results
Osteochondroma∗ DEH MC
Osteochondroma
Antigen Positive % Positive % vs DEH (p value) Positive %
Syndecan-2 15/21 71 8/8 100 0.15 2/2 100
CD44 3/23 13 0/8 0 0.55 0/2 0
CD44v3 19/20 95 8/9 89 0.53 2/2 100
HS chain 4/22 18 1/10 10 1 0/2 0
PTHLH 37/65 57 9/9 100 0.011 2/2 100
PTHR1 12/19 63 6/7 86 0.38 2/2 100
BCL2 3/59 5 4/6 67 0.001 0/1 0
p21 5/20 25 3/7 43 0.63 2/2 100
∗ Data published previously (PTHLH and BCL2 [22], p21 [19]) or unpublished (syndecan-2, CD44, CD44v3, HS chain,
PTHR1).
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Figure 3. Immunohistochemical results. Light micrograph showing PTHLH immunohistochemical staining of (A) hereditary
osteochondroma with very weak PTHLH staining in less than 25% of the cells, scored as negative; (B) DEH lesion scored as
positive. The lesion clearly demonstrates strong PTHLH expression in 75–100% of the cells; (C) MC lesion expressing PTHLH
in almost all cells. Light micrograph showing BCL2 immunohistochemical staining of (D) DEH lesion demonstrating strong BCL2
expression in 75–100% of the cells; (E) MC lesion demonstrating absent or very weak BCL2 expression, but positive internal
controls were present (inset)
DEH clustered separately from osteochondromas as
well as from growth plate samples. More specifically,
in contrast to the generally low EXT expression in
osteochondroma, due to EXT mutations, EXT1 and
EXT2 expression levels in the DEH case were com-
parable to the normal growth plate. This is consis-
tent with the one DEH patient reported with absent
EXT1 and EXT2 mutations [28]. EXT mutations are
hypothesized to result in aberrant HS biosynthesis,
which in turn is expected to affect IHH/PTHLH sig-
nalling. We show that PTHLH signalling molecules
are expressed in DEH at both mRNA (qPCR) and
protein levels (immunohistochemistry). Thus, in con-
trast to osteochondroma, in which PTHLH signalling
J Pathol 2006; 209: 411–419
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Figure 4. Unsupervized hierarchical cluster analysis of cDNA
microarray. DEH and MC cluster together and separately
from osteochondromas, both solitary and hereditary, and
from the growth plates. The cluster represents 5271 spot-
ted cDNA clones that were present in at least 55% of the
samples. GP = growth plate; OC = solitary osteochondroma;
OCmo = hereditary osteochondroma; DEH = dysplasia epi-
physealis hemimelica; MC = metachondromatosis
Table 4. Normalized relative qPCR expression levels (log
transformed) in DEH (case 9), MC (case 11), osteochondroma,











12 12 7 6
EXT1 3.37 ± 0.11 2.71 ± 0.48 3.39 3.17
EXT2 3.05 ± 0.10 2.68 ± 0.52 3.05 2.72
IHH 3.18 ± 0.72 2.92 ± 0.72 2.75 2.92
PTCH 3.34 ± 0.13 3.18 ± 0.31 3.30 2.77
SMO 3.17 ± 0.12 3.23 ± 0.17 3.68 2.74
GLI1 3.01 ± 0.08 2.99 ± 0.23 2.94 2.44
GLI2 3.43 ± 0.17 3.18 ± 0.17 3.22 3.14
GLI3 2.94 ± 0.06 2.90 ± 0.24 3.44 2.81
PTHLH 2.26 ± 0.21 1.89 ± 0.34 2.86 3.23
is downregulated, probably as a result of EXT muta-
tions [19,22], this growth plate signalling pathway
seems operative in DEH. Although patients with osteo-
chondroma were older than those with DEH or MC
lesions in our series, expression patterns did not cor-
relate with patient age or gender, indicating that the
observed differences in expression are independent of
the maturity of the lesions. PTHLH signalling has
also been shown to be active in other cartilaginous
tumours, such as enchondroma and central chondrosar-
coma [19,29], peripheral chondrosarcoma [19], chon-
droblastoma [30], and chondromyxoid fibroma [31],
suggesting that is important not only for normal but
also for neoplastic chondrocyte proliferation.
Little is known about the histogenesis of DEH
and no molecular studies have been reported. Half
a century ago it had already been suggested that
an unknown aetiological factor affects the limb buds
during early fetal life [32,33] and an early postzy-
gotic mutation resulting in asymmetric involvement
of skeletal structures can be expected, as has been
shown, for instance, for polyostotic fibrous dysplasia
(McCune–Albright syndrome) [34]. Silverman sug-
gested that the lesions in DEH result from a defect
in the periosteal ring around the growth cartilage
[7]. Trevor suggested that they result from failure of
the hypertrophic cells in the growth plate to undergo
apoptosis, retaining their power of division [32]. Our
results may favour this hypothesis since we show that
PTHLH signalling is active in DEH. Moreover, we
show that BCL2, an anti-apoptotic protein downstream
of PTHLH, is expressed in four of six DEH cases,
while being mostly absent in osteochondroma [19,22].
In contrast to DEH, MC was histologically simi-
lar to osteochondroma, although only two cases were
available. Clinically, however, MC-related osteochon-
dromas and conventional osteochondromas behave dif-
ferently since they have different predilection sites
and point in different directions. Also, MC-related
osteochondromas have the capacity to regress sponta-
neously, instead of the capacity to become malignant
as is the case for conventional osteochondromas [3].
This difference is confirmed using cDNA microarray
analysis since the MC case clustered together with the
DEH case and demonstrated less resemblance to osteo-
chondromas and growth plates.
EXT mutations were reported to be absent in one
of our MC patients. The EXT genes were normally
expressed, which also confirms that MC is different
from MO. Nothing is known about the underlying gene
defect or the histogenesis of MC-related osteochondro-
mas. No genomic aberrations were found in case 11
(data not shown) using high resolution array compara-
tive genomic hybridization experiments [35]. We show
that the genes involved in IHH and PTHLH signalling
are normally expressed in the two cases we had avail-
able, suggesting that, in contrast to the EXT genes in
MO, the gene responsible for MC will probably not
affect these pathways. Thus, despite the morphological
similarities, MC-related and conventional osteochon-
dromas are different entities.
In conclusion, in a comparative study between
DEH, MC, and osteochondroma, we show that, at
the histological level, clumping of chondrocytes in a
fibrillary matrix are distinguishing features of DEH,
while MC-related and conventional osteochondroma
are histologically identical. At the molecular level,
we show that, in contrast to osteochondroma, the
EXT genes and the downstream PTHLH pathway
are active in MC and DEH, confirming that these
are different entities and suggesting that the so far
unknown molecular defects in these lesions do not
affect EXT signalling.
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